A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants

Exclusion Criteria

• •History of any clinically important disease or disorder.
• •History of acute pancreatitis, chronic pancreatitis, gallstones, or elevation in serum lipase/pancreatic amylase.
• •History or presence of gastrointestinal, hepatic, or renal disease.
• •Clinically significant hepatic disease, inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper gastrointestinal tract.
• •Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.
• •Any clinically important abnormalities in rhythm, blood pressure, heart rate, conduction or morphology of the resting electrocardiogram (ECG).
• •Uncontrolled thyroid disease, defined as thyroid-stimulating hormone \> 6.0 mIU/L or \< 0.4 mIU/L at Screening.
• •Current smokers or known history of alcohol or drug abuse.
• •History of severe allergy/hypersensitivity or excessive intake of caffeine-containing drinks or food.
• •Use of any prescribed or nonprescribed medication including antacids or analgesics.
• •Participants who are on or are planning to undertake a weight loss program.
• •History of psychosis, major depressive disorder, suicide attempt or suicidal ideation within the past year.
• •Lactating, breastfeeding, or pregnant females or females who intend to become pregnant.
• •Participants who are vegans or have medical dietary restrictions.